Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDR Modulation with Valspodar and IL-2 in Untreated AML
NCT00002925Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 1997
- Primary completion
- Nov 2003
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valspodar in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Feb 1997; status: completed.
02
Drugs
valspodar
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00002925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002925.